Gliflozin

Gliflozin drugs are a class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2), and are therefore also called SGLT2 inhibitors. Gliflozins are used in the treatment of type II diabetes mellitus (T2DM). As studied on canagliflozin, a member of this class, gliflozins enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.

The gliflozins are used to treat type 2 diabetes mellitus.

In May 2015, the United States' Food and Drug Administration issued a warning that the gliflozins canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis.

Other side effects of gliflozins include increased risk of urinary tract infections, candidal vulvovaginitis and low blood sugar (hypoglycemia).

Interactions are very important for SGLT2 inhibitors because most T2DM patients are taking many other medications. There is low risk of clinically relevant pharmacokinetics drug interactions because of the metabolic pathway of SGLT2. According to Bhartia and his co-workers, it is safe to consume dapagliflozin along with pioglitazone, metformin, glimepiride, or sitagliptin and dose adjustment is unnecessary for either drug. It is unlikely that food intake has clinical meaningful impact on the efficacy of dapagliflozin, therefore it can be administered without regard to meals.

...
Wikipedia